We provide information, give support, sponsor medical advice and create bonds for families and children with achondroplasia and other forms of rare bone dysplasia
Search ...
EN
ES
PT
Donations
Achondroplasia
About Us
News
Events
Galleries
Library
Contacts
History
How ALPE began. These are our milestones
People
Who we are
Community
Join us
ALPE Support
How we can help
Collaboration
How you can help
Medicine and science
Early intervention
Educacion and society
News
Archive
>> FDA committees conclusions on the open meeting on achondroplasia
>> ALPE summer camp: See you in a year!
>> Clinical trial with Meclozine for achondroplasia
>> Therachon starts a Natural History Study in children with achondroplasia
>> BioMarin starts the phase 2 study BMN 111-206 in infants and toddlers
>> New potential treatment in development for achondroplasia
>> 4th ALPE Awards
>> ALPE participates at the annual convention of the French association APPT
>> ALPE participates in FDA Advisory Committees meeting on achondroplasia
>> Ascendis Pharma starts Phase 1 Trial of TransCon CNP for achondroplasia
>> Request of participation for an international study on Achondroplasia
>> ALPE wins the 10th Social Projects of Santander Bank call
>> Study reveals new information on obesity in achondroplasia and the soluble FGFR3
>> European Pillar of Social Rights
>> Call for the 4th ALPE Awards
>> BioMarin starts LIAISE study on achondroplasia
>> A new clinical trial starts for achondroplasia
>> ALPE representation at the European Parliament in the ERN BOND meeting
>> 1st Meeting of the Multidisciplinary Unit of Skeletal Dysplasias (UMED)
>> The Virtual platform of the European Reference Networks
>> Growing up with a sibling with dwarfism: perceptions of adults non-dwarf siblings
>> BioMarin Achondroplasia Clinical Development Programme Update
>> 3rd Meeting around Achondroplasia in Málaga
>> BioMarin´s Research and Development day 2017 presentation
>> Highlights of the ISDS 2017 meeting
>> New study on Meclozine for achondroplasia
>> International Dwarfism Leadership Summit report
>> BioMarin presents the results of Vosoritide for achondroplasia at the ASHG 2016
>> A new compound NVP-BGJ398 improves the FGFR3 mutation related dwarfism in mice
>> Dr. Avner Yayon interview
>> Potential treatments for achondroplasia
>> Prizes and awards
>> Let the sun rise! Presentation. October 2011
>> Winners of the III ALPE Awards 2016
>> Market research on achondroplasia
>> Sum up of AISAC congress about rare diseases
>> ALPE Foundation in the European Patient Advocacy Groups (ePAGs)
>> Phase 2 results of Vosorotide for achondroplasia
>> About rare diseases
>> Press release on Vosoritide
>> A future for genetic diseases: CRIPSR-Cas9 genome editing
Sign up for regular updates
SUBSCRIBE
